<DOC>
	<DOC>NCT00532350</DOC>
	<brief_summary>This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.</brief_summary>
	<brief_title>Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients between 40 and 80 years of age with controlled COPD. Women must be surgically sterilized or postmenopausal. Additional birth control and postmenopausal information will be available at time of enrollment. Body mass index (BMI) must be within the range of 18 to 32 kg/m2 Participation in any interventional clinical investigation with 4 weeks of study start Blood loss or donation of 400 mL or more within 2 months of study start Significant illness (other than respiratory) within 2 weeks of study start Past medical personal or close family history of clinically significant ECG abnormalities Any medical condition that may interfere with exercise testing or that may make spirometry unsafe A known hypersensitivity to the drug. History of immunocompromise, including a positive HIV test result. History of drug or alcohol abuse within 12 months of study start Any condition that may compromise patient safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>COPD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>plethysmography</keyword>
	<keyword>cycle ergometry</keyword>
	<keyword>exercise testing</keyword>
	<keyword>spirometry</keyword>
</DOC>